This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CDB-2914, ellaOne (EU), emergency contraceptive, Esmya (EU), Fibristal (Canada), PGL4001, ulipristal acetate, UPA UF, VA2914
Description: PGL4001 (Ulipristal) is a selective progesterone receptor modulator (SPRM) which reversibly blocks the progesterone receptor in it target tissues (uterus, cervix, ovaries, hypothalamus) and acts as a potent, orally active antiprogestational agent.
HRA Pharma and PregLem
In December 2007, HRA Pharma announced that it entered into a licensing agreement with PregLem for the European development and commercialisation of HRA Pharma's ulipristal for the treatment of various benign gynecological disorders. HRA Pharma retains the rights for development and commercialisation of ulipristal in the rest of the world. HRA Pharma will receive payments from PregLem upon the achievement of specific development and regulatory milestones as well as royalties on sales.
HRA Pharma and Watson
In February 2010, Watson Pharmaceuticals and HRA Pharma announced an exclusive licensing agreement for Watson to become the commercial partner for ulipristal acetate (UPA) in the U.S.
Under the terms of the licensing agreement, Watson will make payments to HRA Pharma, based on the achievement of certain milestones. In addition, Watson will also pay HRA Pharma a royalty on U.S. sales of the product. Watson will be responsible...See full deal structure in Biomedtracker
Partners: Gedeon Richter Plc HRA Pharma
Additional information available to subscribers only: